Forecast for NINDS Exploratory Grant Program in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Research (P20 - Clinical Trial Optional)
Last verified by NonDilute: 2026-06-08. Official notice and agency instructions control.
If you have a novel hypothesis about ME/CFS mechanisms or diagnostics, NINDS's exploratory P20 pathway funds high-risk pilot work without requiring preliminary data.
Report stale or inaccurate summary
What this is
This NIH/NINDS program targets foundational and exploratory research in ME/CFS pathology, mechanisms, and potential interventions. The P20 mechanism is designed for pilot and feasibility studies that may include optional clinical trial components, making it suitable for researchers developing novel diagnostic tools, biomarkers, or therapeutic approaches. Award amounts and eligibility details are not specified in the source material, but P20 grants typically support smaller, shorter-duration projects ($250K–$500K range over 2–3 years) compared to R01s, making them accessible entry points for emerging research teams.
Who can apply
Eligibility criteria are unspecified in this posting. Typically, NIH grants require domestic institutions (universities, research centers, hospitals, non-profits) with 501(c)(3) status or equivalent. Contact NINDS directly or review the full RFP once posted to confirm eligibility for your organization type and location.
Topics: ME/CFS research · myalgic encephalomyelitis · chronic fatigue syndrome · exploratory grants · NINDS funding · clinical research · biomarkers discovery
Public-source funding discovery only. This summary is generated from public agency data and may be incomplete or stale. NonDilute is not affiliated with, endorsed by, or acting on behalf of any government agency. Official notices and agency instructions control. NonDilute does not determine eligibility, provide grant-writing advice, or guarantee funding.